Active 0 6 0 6 O
central 7 14 7 14 B-chronic_disease
nervous 15 22 15 22 I-chronic_disease
system 23 29 23 29 I-chronic_disease
( 30 31 30 31 I-chronic_disease
CNS 31 34 31 34 I-chronic_disease
) 34 35 34 35 I-chronic_disease
disease 36 43 36 43 I-chronic_disease
in 44 46 44 46 O
patient 47 54 47 54 O
with 55 59 55 59 O
history 60 67 60 67 O
of 68 70 68 70 O
CNS 71 74 71 74 B-cancer
malignancy 75 85 75 85 I-cancer

Acute 0 5 86 91 B-cancer
lymphoblastic 6 19 92 105 I-cancer
leukemia 20 28 106 114 I-cancer
( 29 30 115 116 I-cancer
ALL 30 33 116 119 I-cancer
): 33 35 119 121 I-cancer
induction 36 45 122 131 O
failure 46 53 132 139 O
, 53 54 139 140 O
primary 55 62 141 148 O
refractory 63 73 149 159 O
to 74 76 160 162 O
treatment 77 86 163 172 B-treatment
( 87 88 173 174 O
do 88 90 174 176 O
not 91 94 177 180 O
achieve 95 102 181 188 O
complete 103 111 189 197 O
remission 112 121 198 207 B-treatment
after 122 127 208 213 O
first 128 133 214 219 O
course 134 140 220 226 O
of 141 143 227 229 O
therapy 144 151 230 237 B-treatment
) 151 152 237 238 O
or 153 155 239 241 O
are 156 159 242 245 O
beyond 160 166 246 252 O
first 167 172 253 258 O
remission 173 182 259 268 O
including 183 192 269 278 O
second 193 199 279 285 O
or 200 202 286 288 O
greater 203 210 289 296 O
remission 211 220 297 306 O
or 221 223 307 309 O
active 224 230 310 316 O
disease 231 238 317 324 O

Bilirubin 0 9 325 334 B-clinical_variable
= 10 11 335 336 O
< 11 12 336 337 O
to 13 15 338 340 O
2.0 16 19 341 344 B-upper_bound
x 20 21 345 346 I-upper_bound
normal 22 28 347 353 I-upper_bound

Chronic 0 7 354 361 B-cancer
myeloid 8 15 362 369 I-cancer
leukemia 16 24 370 378 I-cancer
( 25 26 379 380 I-cancer
CML 26 29 380 383 I-cancer
) 29 30 383 384 I-cancer
second 31 37 385 391 O
chronic 38 45 392 399 O
phase 46 51 400 405 O
or 52 54 406 408 O
accelerated 55 66 409 420 O
phase 67 72 421 426 O

Creatinine 0 10 427 437 B-clinical_variable
< 11 12 438 439 O
1.6 13 16 440 443 B-upper_bound
mg 17 19 444 446 I-upper_bound
/ 19 20 446 447 I-upper_bound
dL 20 22 447 449 I-upper_bound

Females 0 7 450 457 B-gender
of 8 10 458 460 O
reproductive 11 23 461 473 O
potential 24 33 474 483 O
must 34 38 484 488 O
adhere 39 45 489 495 O
to 46 48 496 498 O
the 49 52 499 502 O
scheduled 53 62 503 512 O
pregnancy 63 72 513 522 B-pregnancy
testing 73 80 523 530 O
as 81 83 531 533 O
required 84 92 534 542 O
in 93 95 543 545 O
the 96 99 546 549 O
Revlimid 100 108 550 558 O
REMS 109 113 559 563 O
program 114 121 564 571 O

Have 0 4 572 576 O
identified 5 15 577 587 O
a 16 17 588 589 O
backup 18 24 590 596 O
cells 25 30 597 602 O
source 31 37 603 609 O
in 38 40 610 612 O
case 41 45 613 617 O
of 46 48 618 620 O
engraftment 49 60 621 632 B-chronic_disease
failure 61 68 633 640 I-chronic_disease
; 68 69 640 641 O
the 70 73 642 645 O
source 74 80 646 652 O
can 81 84 653 656 O
be 85 87 657 659 O
autologous 88 98 660 670 O
, 98 99 670 671 O
related 100 107 672 679 O
or 108 110 680 682 O
unrelated 111 120 683 692 O

Hodgkin 0 7 693 700 B-cancer
's 7 9 700 702 I-cancer
disease 10 17 703 710 I-cancer
( 18 19 711 712 I-cancer
HD 19 21 712 714 I-cancer
): 21 23 714 716 I-cancer
induction 24 33 717 726 O
failures 34 42 727 735 O
, 42 43 735 736 O
second 44 50 737 743 O
or 51 53 744 746 O
third 54 59 747 752 O
complete 60 68 753 761 O
remission 69 78 762 771 B-treatment
, 78 79 771 772 O
or 80 82 773 775 O
relapse 83 90 776 783 O
( 91 92 784 785 O
including 92 101 785 794 O
relapse 102 109 795 802 O
post 110 114 803 807 B-treatment
autologous 115 125 808 818 I-treatment
hematopoietic 126 139 819 832 I-treatment
stem 140 144 833 837 I-treatment
cell 145 149 838 842 I-treatment
transplant 150 160 843 853 I-treatment
) 160 161 853 854 O

Left 0 4 855 859 B-clinical_variable
ventricular 5 16 860 871 I-clinical_variable
ejection 17 25 872 880 I-clinical_variable
fraction 26 34 881 889 I-clinical_variable
greater 35 42 890 897 O
than 43 47 898 902 O
45 48 50 903 905 B-lower_bound
% 50 51 905 906 I-lower_bound

Men 0 3 907 910 B-gender
must 4 8 911 915 O
agree 9 14 916 921 B-contraception_consent
to 15 17 922 924 I-contraception_consent
use 18 21 925 928 I-contraception_consent
a 22 23 929 930 I-contraception_consent
latex 24 29 931 936 I-contraception_consent
condom 30 36 937 943 I-contraception_consent
during 37 43 944 950 I-contraception_consent
sexual 44 50 951 957 I-contraception_consent
contact 51 58 958 965 I-contraception_consent
with 59 63 966 970 O
females 64 71 971 978 B-gender
of 72 74 979 981 O
child 75 80 982 987 O
bearing 81 88 988 995 O
potential 89 98 996 1005 O
even 99 103 1006 1010 O
if 104 106 1011 1013 O
they 107 111 1014 1018 O
have 112 116 1019 1023 O
had 117 120 1024 1027 O
a 121 122 1028 1029 O
successful 123 133 1030 1040 O
vasectomy 134 143 1041 1050 O

Multiple 0 8 1051 1059 B-cancer
myeloma 9 16 1060 1067 I-cancer
: 16 17 1067 1068 O
stage 18 23 1069 1074 B-lower_bound
II 24 26 1075 1077 I-lower_bound
or 27 29 1078 1080 O
III 30 33 1081 1084 B-upper_bound
, 33 34 1084 1085 O
symptomatic 35 46 1086 1097 B-chronic_disease
, 46 47 1097 1098 O
secretory 48 57 1099 1108 B-clinical_variable
multiple 58 66 1109 1117 I-clinical_variable
myeloma 67 74 1118 1125 I-clinical_variable
requiring 75 84 1126 1135 O
treatment 85 94 1136 1145 B-treatment

Myelodysplastic 0 15 1146 1161 B-cancer
syndrome 16 24 1162 1170 I-cancer
( 25 26 1171 1172 I-cancer
MDS 26 29 1172 1175 I-cancer
): 29 31 1175 1177 I-cancer
primary 32 39 1178 1185 O
or 40 42 1186 1188 O
therapy 43 50 1189 1196 B-treatment
related 51 58 1197 1204 O

Negative 0 8 1205 1213 B-clinical_variable
beta 9 13 1214 1218 I-clinical_variable
human 14 19 1219 1224 I-clinical_variable
chorionic 20 29 1225 1234 I-clinical_variable
gonadotropin 30 42 1235 1247 I-clinical_variable
( 43 44 1248 1249 I-clinical_variable
HCG 44 47 1249 1252 I-clinical_variable
) 47 48 1252 1253 I-clinical_variable
test 49 53 1254 1258 O
in 54 56 1259 1261 O
a 57 58 1262 1263 O
woman 59 64 1264 1269 B-gender
with 65 69 1270 1274 O
child 70 75 1275 1280 O
bearing 76 83 1281 1288 O
potential 84 93 1289 1298 O
defined 94 101 1299 1306 O
as 102 104 1307 1309 O
not 105 108 1310 1313 O
post 109 113 1314 1318 O
- 113 114 1318 1319 O
menopausal 114 124 1319 1329 O
for 125 128 1330 1333 O
24 129 131 1334 1336 B-upper_bound
months 132 138 1337 1343 I-upper_bound
or 139 141 1344 1346 O
no 142 144 1347 1349 O
previous 145 153 1350 1358 O
surgical 154 162 1359 1367 B-treatment
sterilization 163 176 1368 1381 I-treatment
and 177 180 1382 1385 O
willing 181 188 1386 1393 O
to 189 191 1394 1396 O
ongoing 192 199 1397 1404 O
pregnancy 200 209 1405 1414 B-pregnancy
testing 210 217 1415 1422 O
while 218 223 1423 1428 O
on 224 226 1429 1431 O
treatment 227 236 1432 1441 O
with 237 241 1442 1446 O
lenalidomide 242 254 1447 1459 B-treatment

Non 0 3 1460 1463 B-cancer
- 3 4 1463 1464 I-cancer
Hodgkin 4 11 1464 1471 I-cancer
's 11 13 1471 1473 I-cancer
lymphoma 14 22 1474 1482 I-cancer
( 23 24 1483 1484 I-cancer
NHL 24 27 1484 1487 I-cancer
) 27 28 1487 1488 I-cancer
in 29 31 1489 1491 O
second 32 38 1492 1498 O
or 39 41 1499 1501 O
third 42 47 1502 1507 O
complete 48 56 1508 1516 O
remission 57 66 1517 1526 B-treatment
, 66 67 1526 1527 O
refractory 68 78 1528 1538 B-cancer
NHL 79 82 1539 1542 I-cancer
, 82 83 1542 1543 O
or 84 86 1544 1546 O
relapsed 87 95 1547 1555 B-cancer
NHL 96 99 1556 1559 I-cancer
( 100 101 1560 1561 O
including 101 110 1561 1570 O
relapse 111 118 1571 1578 O
post 119 123 1579 1583 B-treatment
autologous 124 134 1584 1594 I-treatment
hematopoietic 135 148 1595 1608 I-treatment
stem 149 153 1609 1613 I-treatment
cell 154 158 1614 1618 I-treatment
transplant 159 169 1619 1629 I-treatment
) 169 170 1629 1630 O
; 170 171 1630 1631 O
double 172 178 1632 1638 B-cancer
hit 179 182 1639 1642 I-cancer
lymphomas 183 192 1643 1652 I-cancer
in 193 195 1653 1655 O
first 196 201 1656 1661 O
remission 202 211 1662 1671 O
or 212 214 1672 1674 O
more 215 219 1675 1679 O
advanced 220 228 1680 1688 B-cancer
disease 229 236 1689 1696 I-cancer

Patients 0 8 1697 1705 O
must 9 13 1706 1710 O
have 14 18 1711 1715 O
one 19 22 1716 1719 O
of 23 25 1720 1722 O
the 26 29 1723 1726 O
following 30 39 1727 1736 O
hematologic 40 51 1737 1748 B-cancer
malignancies 52 64 1749 1761 I-cancer
: 64 65 1761 1762 O
acute 66 71 1763 1768 B-cancer
myelogenous 72 83 1769 1780 I-cancer
leukemia 84 92 1781 1789 I-cancer
( 93 94 1790 1791 I-cancer
AML 94 97 1791 1794 I-cancer
) 97 98 1794 1795 I-cancer
, 98 99 1795 1796 O
induction 100 109 1797 1806 O
failure 110 117 1807 1814 O
, 117 118 1814 1815 O
high 119 123 1816 1820 O
- 123 124 1820 1821 O
risk 124 128 1821 1825 O
for 129 132 1826 1829 O
relapse 133 140 1830 1837 O
first 141 146 1838 1843 O
remission 147 156 1844 1853 O
( 157 158 1854 1855 O
with 158 162 1855 1859 O
intermediate 163 175 1860 1872 O
- 175 176 1872 1873 O
risk 176 180 1873 1877 O
or 181 183 1878 1880 O
high 184 188 1881 1885 O
- 188 189 1885 1886 O
risk 189 193 1886 1890 O
cytogenetics 194 206 1891 1903 O
, 206 207 1903 1904 O
fms 208 211 1905 1908 B-treatment
- 211 212 1908 1909 I-treatment
related 212 219 1909 1916 I-treatment
tyrosine 220 228 1917 1925 I-treatment
kinase 229 235 1926 1932 I-treatment
3 236 237 1933 1934 I-treatment
[ 238 239 1935 1936 I-treatment
FLT3 239 243 1936 1940 I-treatment
] 243 244 1940 1941 I-treatment
mutation 245 253 1942 1950 O
positive 254 262 1951 1959 O
and/or 263 269 1960 1966 O
evidence 270 278 1967 1975 O
of 279 281 1976 1978 O
minimal 282 289 1979 1986 B-chronic_disease
residual 290 298 1987 1995 I-chronic_disease
disease 299 306 1996 2003 I-chronic_disease
by 307 309 2004 2006 O
flow 310 314 2007 2011 O
cytometry 315 324 2012 2021 O
) 324 325 2021 2022 O
, 325 326 2022 2023 O
secondary 327 336 2024 2033 O
leukemia 337 345 2034 2042 O
from 346 350 2043 2047 O
prior 351 356 2048 2053 B-treatment
chemotherapy 357 369 2054 2066 I-treatment
and/or 370 376 2067 2073 O
arising 377 384 2074 2081 O
from 385 389 2082 2086 O
myelodysplastic 390 405 2087 2102 B-cancer
syndrome 406 414 2103 2111 I-cancer
, 414 415 2111 2112 O
any 416 419 2113 2116 O
disease 420 427 2117 2124 O
beyond 428 434 2125 2131 O
first 435 440 2132 2137 O
remission 441 450 2138 2147 O

Patients 0 8 2148 2156 O
must 9 13 2157 2161 O
have 14 18 2162 2166 O
two 19 22 2167 2170 O
CB 23 25 2171 2173 O
units 26 31 2174 2179 O
available 32 41 2180 2189 O
which 42 47 2190 2195 O
are 48 51 2196 2199 O
matched 52 59 2200 2207 O
with 60 64 2208 2212 O
the 65 68 2213 2216 O
patient 69 76 2217 2224 O
at 77 79 2225 2227 O
4 80 81 2228 2229 B-lower_bound
, 81 82 2229 2230 O
5 83 84 2231 2232 O
, 84 85 2232 2233 O
or 86 88 2234 2236 O
6/6 89 92 2237 2240 B-upper_bound
human 93 98 2241 2246 B-clinical_variable
leukocyte 99 108 2247 2256 I-clinical_variable
antigen 109 116 2257 2264 I-clinical_variable
( 117 118 2265 2266 I-clinical_variable
HLA 118 121 2266 2269 I-clinical_variable
) 121 122 2269 2270 I-clinical_variable
class 123 128 2271 2276 I-clinical_variable
I 129 130 2277 2278 I-clinical_variable
( 131 132 2279 2280 I-clinical_variable
serological 132 143 2280 2291 I-clinical_variable
) 143 144 2291 2292 I-clinical_variable
and 145 148 2293 2296 I-clinical_variable
II 149 151 2297 2299 I-clinical_variable
( 152 153 2300 2301 I-clinical_variable
molecular 153 162 2301 2310 I-clinical_variable
) 162 163 2310 2311 I-clinical_variable
antigens 164 172 2312 2320 I-clinical_variable
; 172 173 2320 2321 O
each 174 178 2322 2326 O
cord 179 183 2327 2331 O
must 184 188 2332 2336 O
contain 189 196 2337 2344 O
at 197 199 2345 2347 O
least 200 205 2348 2353 O
1.5 206 209 2354 2357 B-lower_bound
x 210 211 2358 2359 I-lower_bound
10 212 214 2360 2362 I-lower_bound
^ 214 215 2362 2363 I-lower_bound
7 215 216 2363 2364 I-lower_bound
total 217 222 2365 2370 B-clinical_variable
nucleated 223 232 2371 2380 I-clinical_variable
cells 233 238 2381 2386 I-clinical_variable
/ 238 239 2386 2387 I-clinical_variable
Kg 239 241 2387 2389 I-clinical_variable
recipient 242 251 2390 2399 O
body 252 256 2400 2404 O
weight 257 263 2405 2411 O
( 264 265 2412 2413 O
pre 265 268 2413 2416 O
- 268 269 2416 2417 O
thaw 269 273 2417 2421 O
) 273 274 2421 2422 O
; 274 275 2422 2423 O
cord 276 280 2424 2428 O
blood 281 286 2429 2434 O
units 287 292 2435 2440 O
will 293 297 2441 2445 O
be 298 300 2446 2448 O
procured 301 309 2449 2457 O
through 310 317 2458 2465 O
the 318 321 2466 2469 O
National 322 330 2470 2478 O
Marrow 331 337 2479 2485 O
Donor 338 343 2486 2491 O
Program 344 351 2492 2499 O
( 352 353 2500 2501 O
NMDP 353 357 2501 2505 O
) 357 358 2505 2506 O

Patients 0 8 2507 2515 O
who 9 12 2516 2519 O
have 13 17 2520 2524 O
had 18 21 2525 2528 O
a 22 23 2529 2530 O
prior 24 29 2531 2536 B-treatment
autologous 30 40 2537 2547 I-treatment
transplant 41 51 2548 2558 I-treatment

Patients 0 8 2559 2567 O
with 9 13 2568 2572 O
chronic 14 21 2573 2580 B-chronic_disease
active 22 28 2581 2587 I-chronic_disease
hepatitis 29 38 2588 2597 I-chronic_disease
or 39 41 2598 2600 O
cirrhosis 42 51 2601 2610 B-chronic_disease

Patients 0 8 2611 2619 O
with 9 13 2620 2624 O
known 14 19 2625 2630 O
history 20 27 2631 2638 O
of 28 30 2639 2641 O
human 31 36 2642 2647 B-chronic_disease
immunodeficiency 37 53 2648 2664 I-chronic_disease
virus 54 59 2665 2670 I-chronic_disease
( 60 61 2671 2672 I-chronic_disease
HIV)/acquired 61 74 2672 2685 I-chronic_disease
immune 75 81 2686 2692 I-chronic_disease
deficiency 82 92 2693 2703 I-chronic_disease
syndrome 93 101 2704 2712 I-chronic_disease
( 102 103 2713 2714 I-chronic_disease
AIDS 103 107 2714 2718 I-chronic_disease
) 107 108 2718 2719 I-chronic_disease

Patients 0 8 2720 2728 O
with 9 13 2729 2733 O
known 14 19 2734 2739 O
hypersensitivity 20 36 2740 2756 O
to 37 39 2757 2759 O
lenalidomide 40 52 2760 2772 B-allergy_name
and/or 53 59 2773 2779 O
rituximab 60 69 2780 2789 B-allergy_name

Performance 0 11 2790 2801 B-clinical_variable
score 12 17 2802 2807 I-clinical_variable
of 18 20 2808 2810 O
at 21 23 2811 2813 O
least 24 29 2814 2819 O
80 30 32 2820 2822 B-lower_bound
% 32 33 2822 2823 I-lower_bound
by 34 36 2824 2826 O
Karnofsky 37 46 2827 2836 B-clinical_variable
or 47 49 2837 2839 O
0 50 51 2840 2841 O
to 52 54 2842 2844 O
2 55 56 2845 2846 B-upper_bound
Eastern 57 64 2847 2854 B-clinical_variable
Cooperative 65 76 2855 2866 I-clinical_variable
Oncology 77 85 2867 2875 I-clinical_variable
Group 86 91 2876 2881 I-clinical_variable
( 92 93 2882 2883 I-clinical_variable
ECOG 93 97 2883 2887 I-clinical_variable
) 97 98 2887 2888 I-clinical_variable

Pulmonary 0 9 2889 2898 O
function 10 18 2899 2907 O
test 19 23 2908 2912 O
( 24 25 2913 2914 O
PFT 25 28 2914 2917 O
) 28 29 2917 2918 O
demonstrating 30 43 2919 2932 O
a 44 45 2933 2934 O
diffusion 46 55 2935 2944 B-clinical_variable
capacity 56 64 2945 2953 I-clinical_variable
of 65 67 2954 2956 O
least 68 73 2957 2962 O
45 74 76 2963 2965 B-lower_bound
% 76 77 2965 2966 I-lower_bound
predicted 78 87 2967 2976 O

Serum 0 5 2977 2982 B-clinical_variable
glutamate 6 15 2983 2992 I-clinical_variable
pyruvate 16 24 2993 3001 I-clinical_variable
transaminase 25 37 3002 3014 I-clinical_variable
( 38 39 3015 3016 I-clinical_variable
SGPT 39 43 3016 3020 I-clinical_variable
) 43 44 3020 3021 I-clinical_variable
= 45 46 3022 3023 O
< 46 47 3023 3024 O
to 48 50 3025 3027 O
2.0 51 54 3028 3031 B-upper_bound
x 55 56 3032 3033 I-upper_bound
normal 57 63 3034 3040 I-upper_bound

Small 0 5 3041 3046 B-cancer
lymphocytic 6 17 3047 3058 I-cancer
lymphoma 18 26 3059 3067 I-cancer
( 27 28 3068 3069 I-cancer
SLL 28 31 3069 3072 I-cancer
) 31 32 3072 3073 I-cancer
, 32 33 3073 3074 O
or 34 36 3075 3077 O
chronic 37 44 3078 3085 B-cancer
lymphocytic 45 56 3086 3097 I-cancer
leukemia 57 65 3098 3106 I-cancer
( 66 67 3107 3108 I-cancer
CLL 67 70 3108 3111 I-cancer
) 70 71 3111 3112 I-cancer
with 72 76 3113 3117 O
progressive 77 88 3118 3129 B-chronic_disease
disease 89 96 3130 3137 I-chronic_disease
following 97 106 3138 3147 O
standard 107 115 3148 3156 B-treatment
therapy 116 123 3157 3164 I-treatment

Woman 0 5 3165 3170 B-gender
with 6 10 3171 3175 O
child 11 16 3176 3181 O
bearing 17 24 3182 3189 O
potential 25 34 3190 3199 O
must 35 39 3200 3204 O
either 40 46 3205 3211 O
commit 47 53 3212 3218 B-contraception_consent
to 54 56 3219 3221 I-contraception_consent
continued 57 66 3222 3231 I-contraception_consent
abstinence 67 77 3232 3242 I-contraception_consent
from 78 82 3243 3247 O
heterosexual 83 95 3248 3260 O
intercourse 96 107 3261 3272 O
or 108 110 3273 3275 O
begin 111 116 3276 3281 B-contraception_consent
TWO 117 120 3282 3285 I-contraception_consent
acceptable 121 131 3286 3296 I-contraception_consent
methods 132 139 3297 3304 I-contraception_consent
of 140 142 3305 3307 I-contraception_consent
birth 143 148 3308 3313 I-contraception_consent
control 149 156 3314 3321 I-contraception_consent
, 156 157 3321 3322 O
one 158 161 3323 3326 O
highly 162 168 3327 3333 O
effective 169 178 3334 3343 O
method 179 185 3344 3350 O
and 186 189 3351 3354 O
one 190 193 3355 3358 O
additional 194 204 3359 3369 O
effective 205 214 3370 3379 O
method 215 221 3380 3386 O
AT 222 224 3387 3389 O
THE 225 228 3390 3393 O
SAME 229 233 3394 3398 O
TIME 234 238 3399 3403 O
, 238 239 3403 3404 O
at 240 242 3405 3407 O
least 243 248 3408 3413 O
4 249 250 3414 3415 B-lower_bound
weeks 251 256 3416 3421 I-lower_bound
before 257 263 3422 3428 O
she 264 267 3429 3432 O
starts 268 274 3433 3439 O
taking 275 281 3440 3446 O
lenalidomide 282 294 3447 3459 B-treatment

patients 0 8 3460 3468 O
with 9 13 3469 3473 O
progressive 14 25 3474 3485 O
CLL 26 29 3486 3489 B-cancer
following 30 39 3490 3499 O
standard 40 48 3500 3508 B-treatment
therapy 49 56 3509 3516 I-treatment
who 57 60 3517 3520 O
meet 61 65 3521 3525 O
European 66 74 3526 3534 B-treatment
Bone 75 79 3535 3539 I-treatment
Marrow 80 86 3540 3546 I-treatment
Transplant 87 97 3547 3557 I-treatment
( 98 99 3558 3559 I-treatment
EBMT 99 103 3559 3563 I-treatment
) 103 104 3563 3564 I-treatment
consensus 105 114 3565 3574 O
guidelines 115 125 3575 3585 O
of 126 128 3586 3588 O
indications 129 140 3589 3600 O
for 141 144 3601 3604 O
allogeneic 145 155 3605 3615 B-treatment
stem 156 160 3616 3620 I-treatment
cell 161 165 3621 3625 I-treatment
transplantation 166 181 3626 3641 I-treatment
; 181 182 3641 3642 O
this 183 187 3643 3647 O
includes 188 196 3648 3656 O
patients 197 205 3657 3665 O
with 206 210 3666 3670 O
( 211 212 3671 3672 O
1 212 213 3672 3673 O
) 213 214 3673 3674 O
lack 215 219 3675 3679 O
of 220 222 3680 3682 O
response 223 231 3683 3691 O
or 232 234 3692 3694 O
early 235 240 3695 3700 O
relapse 241 248 3701 3708 O
within 249 255 3709 3715 O
1 256 257 3716 3717 B-upper_bound
year 258 262 3718 3722 I-upper_bound
of 263 265 3723 3725 O
receiving 266 275 3726 3735 O
a 276 277 3736 3737 O
purine 278 284 3738 3744 B-treatment
analog 285 291 3745 3751 I-treatment
- 291 292 3751 3752 I-treatment
containing 292 302 3752 3762 I-treatment
treatment 303 312 3763 3772 I-treatment
regimen 313 320 3773 3780 I-treatment
, 320 321 3780 3781 O
( 322 323 3782 3783 O
2 323 324 3783 3784 O
) 324 325 3784 3785 O
disease 326 333 3786 3793 O
relapse 334 341 3794 3801 O
within 342 348 3802 3808 O
2 349 350 3809 3810 B-upper_bound
years 351 356 3811 3816 I-upper_bound
of 357 359 3817 3819 O
receiving 360 369 3820 3829 O
a 370 371 3830 3831 O
purine 372 378 3832 3838 B-treatment
analog 379 385 3839 3845 I-treatment
combination 386 397 3846 3857 I-treatment
therapy 398 405 3858 3865 I-treatment
or 406 408 3866 3868 O
after 409 414 3869 3874 O
other 415 420 3875 3880 O
therapies 421 430 3881 3890 B-treatment
such 431 435 3891 3895 O
as 436 438 3896 3898 O
autologous 439 449 3899 3909 B-treatment
stem 450 454 3910 3914 I-treatment
cell 455 459 3915 3919 I-treatment
transplantation 460 475 3920 3935 I-treatment
, 475 476 3935 3936 O
and 477 480 3937 3940 O
( 481 482 3941 3942 O
3 482 483 3942 3943 O
) 483 484 3943 3944 O
CLL 485 488 3945 3948 O
associated 489 499 3949 3959 O
with 500 504 3960 3964 O
tumor 505 510 3965 3970 O
protein 511 518 3971 3978 O
( 519 520 3979 3980 O
p)53 520 524 3980 3984 O
mutations 525 534 3985 3994 O
or 535 537 3995 3997 O
deletions 538 547 3998 4007 O
and/or 548 554 4008 4014 O
deletion 555 563 4015 4023 O
( 564 565 4024 4025 O
del 565 568 4025 4028 O
) 568 569 4028 4029 O
( 570 571 4030 4031 O
17p 571 574 4031 4034 O
) 574 575 4034 4035 O
requiring 576 585 4036 4045 O
therapy 586 593 4046 4053 O
; 593 594 4053 4054 O
patients 595 603 4055 4063 O
must 604 608 4064 4068 O
have 609 613 4069 4073 O
chemosensitive 614 628 4074 4088 B-cancer
disease 629 636 4089 4096 I-cancer
with 637 641 4097 4101 O
at 642 644 4102 4104 O
least 645 650 4105 4110 O
a 651 652 4111 4112 O
partial 653 660 4113 4120 O
response 661 669 4121 4129 O
( 670 671 4130 4131 O
PR 671 673 4131 4133 O
) 673 674 4133 4134 O
or 675 677 4135 4137 O
stable 678 684 4138 4144 O
disease 685 692 4145 4152 O
( 693 694 4153 4154 O
SD 694 696 4154 4156 O
) 696 697 4156 4157 O
with 698 702 4158 4162 O
last 703 707 4163 4167 B-treatment
treatment 708 717 4168 4177 I-treatment
regimen 718 725 4178 4185 I-treatment

